# Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

> **NCT05223088** · PHASE2 · COMPLETED · sponsor: **Fujian Cancer Hospital** · enrollment: 40 (actual)

## Conditions studied

- Immunotherapy
- Gastrict Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Apatinib Mesylate
- **DRUG:** oxaliplatin
- **DRUG:** Tegafur

## Key facts

- **NCT ID:** NCT05223088
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-31
- **Primary completion:** 2023-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223088, "Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05223088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*